Skip to content

Nuvalent, Inc. NUVL Preferred Stock

Preferred Stock at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$0
Exelixis logo
ExelixisEXEL
$0
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$0
Incyte logo
IncyteINCY
$0
ALN
Alnylam PharmaceuticalsALNY
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s preferred stock?
Nuvalent, Inc. (NUVL) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.